Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc. (BCRX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its primary commercial product is ORLADEYO (berotralstat), an oral therapy for HAE. The company also maintains a pipeline of product candidates including navenibart (acquired via merger), BCX17725, avoralstat, and STAR-0310.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenues | $874.8 million | $450.7 million |
| Net Income (Loss) | $263.9 million | ($88.9 million) |
| Operating Income (Loss) | $341.0 million | ($2.5 million) |
| Net Cash Provided by Operating Activities | $347.4 million | ($52.0 million) |
| Cash, Cash Equivalents, and Investments | $335.9 million | $341.2 million |
| Total Assets | $514.2 million | $490.4 million |
| Total Liabilities | $633.3 million | $966.4 million |
| Stockholders' Deficit | ($119.2 million) | ($475.9 million) |
Revenue Composition (2025): Product sales (net) were $623.2 million, primarily driven by ORLADEYO. License and other revenues were $251.7 million, significantly boosted by a $243.3 million license fee from the sale of the European ORLADEYO business.
Material Changes vs. Prior Period
- Profitability Turnaround: The company achieved a net income of $263.9 million in 2025, compared to a net loss of $88.9 million in 2024. This marks the first annual net income on a U.S. GAAP basis.
- Revenue Surge: Total revenues increased 94% year-over-year. This was driven by a $244.0 million increase in license revenue (due to the Neopharmed transaction) and a $168.7 million increase in ORLADEYO product sales (excluding the divested European business).
- Divestiture of European Business: On October 1, 2025, BioCryst sold its European ORLADEYO business to Neopharmed Gentili S.p.A. for total cash proceeds of $254.5 million. This transaction generated significant license revenue and a $3.6 million gain on sale.
- Debt Restructuring: The company fully repaid its $198.7 million Pharmakon Term Loan in October 2025 using proceeds from the European divestiture. This resulted in a one-time loss on extinguishment of debt of $17.3 million but significantly reduced interest expense.
- Merger with Astria: On January 23, 2026 (subsequent to the reporting period), BioCryst completed a merger with Astria Therapeutics, Inc., acquiring navenibart and STAR-0310. This was funded by a new $400 million Blackstone Loan Agreement.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- ORLADEYO Growth: Management anticipates the global commercial market for ORLADEYO has the potential to reach a peak of $1 billion in annual net revenues. Recent data shows increased physician willingness to prescribe and strong patient preference for oral prophylaxis.
- Pipeline Progress:
- ORLADEYO: FDA approved an oral pellet formulation for pediatric patients aged 2 to <12 years in December 2025.
- Navenibart: Acquired via the Astria merger; Phase 3 interim results showed sustained HAE attack suppression with every 3- and 6-month dosing.
- BCX17725: Phase 1 trial for Netherton syndrome is ongoing; data expected by end of 2026.
- Avoralstat: Phase 1 trial for diabetic macular edema is ongoing; company plans to seek a strategic partner for development beyond Phase 1.
- Liquidity: Management believes financial resources are sufficient to fund operations for at least the next 12 months.
Key Risks and Contingencies:
- Patent Litigation: Annora Pharma filed a Paragraph IV certification challenging four ORLADEYO patents (expiring 2039). BioCryst filed a patent infringement lawsuit in March 2025. The outcome is uncertain and could impact future exclusivity.
- Merger Integration: Risks associated with integrating Astria Therapeutics, including potential failure to realize anticipated synergies and increased costs.
- Debt Covenants: The new Blackstone Loan Agreement ($400 million) contains restrictive covenants limiting asset dispositions, additional indebtedness, and dividends. Substantially all assets are pledged as collateral.
- Regulatory & Pricing: Risks related to the Inflation Reduction Act (IRA), potential price negotiations, and reimbursement changes in the U.S. and globally.
- Third-Party Dependence: Reliance on a single specialty pharmacy for U.S. distribution and third-party manufacturers for production.
Investor Verification Checklist
- Verify Patent Litigation Status: Monitor the progress of the lawsuit against Annora Pharma regarding ORLADEYO patents expiring in 2039.
- Assess Merger Integration: Review post-merger financials to confirm the realization of synergies and the successful integration of Astria's assets (navenibart, STAR-0310).
- Monitor Debt Covenants: Track compliance with the Blackstone Loan Agreement covenants, particularly regarding asset sales and additional indebtedness.
- Track ORLADEYO Pediatric Adoption: Evaluate sales performance of the newly approved oral pellet formulation for pediatric patients (2 to <12 years).
- Review Royalty Obligations: Confirm the impact of ongoing royalty payments to RPI and OMERS on net margins as ORLADEYO sales grow.
- Strategic Partnerships: Verify the status of seeking a strategic partner for avoralstat development beyond Phase 1.